Natural Single-Domain Antibody-Nanobody: A Novel Concept in the Antibody Field
Since the serendipitous discovery of heavy-chain antibodies in Camelidae 20 years ago, the smallest single-domain antigen-binding fragment, known as VHH or nanobody, has received growing attention. In comparison with traditional antibodies, VHHs performs equally high specificity and affinity and low toxicity to targets, and has the ability to inhibit the formation of enzymes and enter the receptor gap. Hence, VHHs has been recently regarded as the highly valued protein and applied in multiple fields, including fundamental research, diagnosis, therapeutics, food science, etc. Today, based on the past achievements, an increasing number of academic and industrial groups begin to explore innovative VHH applications. In this review, we make a thorough retrospect of the unique features and explore novel implementations of VHHs in diverse forms in different fields. In addition, we also propose the potential future issues and problems of VHHs in many fields.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Review Article
Publication date: January 1, 2018
More about this publication?
- Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites